<PAGE>
 
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                        
                                 FORM 10-Q/A2
     MARK ONE
     [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                      THE SECURITIES EXCHANGE ACT OF 1934

     For the quarterly period ended December 31, 1997

                                      OR

     [ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
              THE SECURITIES EXCHANGE ACT OF 1934

     For the transition period from _______ to ______

                         Commission File Number 0-17822

                                 SYNETIC, INC.
            (Exact name of registrant as specified in its charter)


     Delaware                           22-2975182
(State or other jurisdiction of       (I.R.S. Employer
incorporation or organization)       Identification No.)


     River Drive Center 2
     669 River Drive
     Elmwood Park, New Jersey               07407
(Address of principal executive offices)  (Zip code)

Registrant's telephone number, including area code:  (201) 703-3400

      Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days.  Yes  X   No ___
                                        ---        

      Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.

           Class                  Outstanding at February 10, 1998
     ---------------------        --------------------------------
Common Stock                             17,683,714 shares
par value $.01 per share
<PAGE>
 
                        SYNETIC, INC. AND SUBSIDIARIES

                                     Index
                                     -----
                                                                       Page
                                                                       ----
Part I.  FINANCIAL INFORMATION:

         Item 1.  Financial Statements
 
         Consolidated Balance Sheets --
              December 31, 1997 and June 30, 1997                      3
 
         Consolidated Statements of Income --
              Six Months Ended December 31, 1997 and 1996              5
 
         Consolidated Statements of Cash Flows --
              Six Months Ended December 31, 1997 and 1996              6
 
         Notes to Consolidated Financial Statements                    7
 
         Item 2.  Management's Discussion and
                      Analysis of Results of Operations and
                      Financial Condition                              9
 
Part II.  OTHER INFORMATION

          Item 6.  Exhibits and Reports on Form 8-K                    11

                   ----------------------------------------

     This report contains certain forward-looking statements and information
relating to Synetic, Inc. (the "Company" or "Synetic") that are based on the
beliefs of the Company's management as well as assumptions made by and
information currently available to the Company's management.  When used in this
report, the words "anticipate", "believe", "estimate", "expect" and similar
expressions, as they relate to the Company or the Company's management, are
intended to identify forward-looking statements.  Such statements reflect the
current view of the Company's management with respect to future events and the
Company's future performance and are subject to certain risks, uncertainties and
assumptions.  Should management's current view of the future or underlying
assumptions prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or expected.  The Company
does not intend to update these forward-looking statements.
<PAGE>
 
                         SYNETIC, INC. AND SUBSIDIARIES
                          CONSOLIDATED BALANCE SHEETS
                                 (in thousands)

                                     ASSETS
<TABLE>
<CAPTION>
 
                                         December 31,   June 30,
                                             1997         1997
                                         -------------  ---------
                                          (unaudited)
<S>                                      <C>            <C>
CURRENT ASSETS:
 Cash and cash equivalents.............      $ 76,641   $ 77,303
 Marketable securities.................         9,900     11,765
 Accounts receivable, net of
   allowances for doubtful accounts
   and sales returns of $782 and $739
   at December 31, 1997 and June 30,
   1997, respectively..................         9,249      9,094
 Inventories...........................         5,906      5,505
 Other current assets..................        11,267      9,233
                                             --------   --------
   Total current assets................       112,963    112,900
                                             --------   --------
 
PROPERTY, PLANT AND EQUIPMENT:
 Land and improvements.................         1,606      1,613
 Building and improvements.............        10,301      9,911
 Machinery and equipment...............        26,134     23,444
 Furniture and fixtures................         3,546      3,283
 Construction in progress..............         3,194      2,516
                                             --------   --------
                                               44,781     40,767
 Less:  Accumulated depreciation.......       (20,026)   (18,681)
                                             --------   --------
 
   Property, plant and equipment, net..        24,755     22,086
                                             --------   --------
 
OTHER ASSETS:
 Marketable securities.................       226,799    226,760
 Other.................................        19,662     20,357
                                             --------   --------
   Total other assets                         246,461    247,117
                                             --------   --------
                                             $384,179   $382,103
                                             ========   ========
 
</TABLE>

The accompanying notes are an integral part of these consolidated balance
sheets.

                                      -3-
<PAGE>
 
                         SYNETIC, INC. AND SUBSIDIARIES
                          CONSOLIDATED BALANCE SHEETS
                     (in thousands, except per share data)

                      LIABILITIES AND STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
 
                                                  December 31,   June 30,
                                                      1997         1997
                                                  -------------  ---------
                                                   (unaudited)
<S>                                               <C>            <C>    
CURRENT LIABILITIES:
 Accounts payable...............................      $  1,545   $  2,344
 Accrued liabilities............................        17,561     14,203
 Income taxes payable...........................         4,756      3,044
                                                      --------   --------
   Total current liabilities....................        23,862     19,591
                                                      --------   --------
 
LONG-TERM DEBT, LESS CURRENT PORTION............       159,500    165,000
 
DEFERRED TAXES AND OTHER LIABILITIES............         5,692      8,776
 
STOCKHOLDERS' EQUITY:
 Preferred stock, $.01 par value;
   10,000,000 shares authorized; none
   issued.......................................             -          -
 Common stock $.01 par value; 50,000,000
   shares authorized; 22,935,919 and
   22,865,149 shared issued; 17,661,456 and
   17,564,980 shares issued and outstanding
   at December 31, 1997 and June 30, 1997,
   respectively.................................           229        229
 Paid-in capital................................       197,857    196,212
 Treasury stock, at cost; 5,274,463 and
   5,300,169 shares at December 31, 1997 and
   June 30, 1997, respectively..................       (38,503)   (39,462)
 Retained earnings..............................        35,542     31,757
                                                      --------   --------
   Total stockholders' equity...................       195,125    188,736   
                                                      --------   --------   
                                                      $384,179   $382,103    
</TABLE>                                              ========   ======== 


The accompanying notes are an integral part of these consolidated balance
sheets.

                                      -4-
<PAGE>                                
 
                        SYNETIC, INC. AND SUBSIDIARIES
                       CONSOLIDATED STATEMENTS OF INCOME
            Quarters and Six Months Ended December 31, 1997 and 1996
                     (in thousands, except per share data)
                                  (unaudited)

<TABLE>
<CAPTION>
 
 
                                                Quarters Ended           Six Months Ended
                                                 December 31,              December 31,
                                             1997           1996         1997       1996
                                         ------------  -------------  ---------  ---------
<S>                                      <C>           <C>            <C>        <C>
                                                      
Net sales..............................      $ 15,440   $ 11,899   $ 30,273   $ 23,084
                                                       
  Cost of sales........................         8,055      6,348     16,371     12,474
  Selling, general and administrative..         7,070      3,839     13,752      7,590
  Interest and other income............        (4,998)    (2,343)   (10,004)    (4,562)
  Interest expense.....................         2,187          -      4,378          -
  Other expense........................             -     28,600          -     28,600
                                             --------   --------   --------   --------
                                               12,314    (36,444)    24,497    (44,102)
                                             --------   --------   --------   --------
                                                       
Income (loss) before provision                         
  for income taxes.....................         3,126    (24,545)     5,776    (21,018)
                                                       
Provision for income taxes.............         1,189      1,389      2,347      2,527
                                             --------   --------   --------   --------
Income (loss) before extraordinary                     
  item.................................      $  1,937   $(25,934)  $  3,429   $(23,545)
                                             ========   ========   ========   ========
                                                       
Extraordinary item:                                    
  Gain from the repurchase of                          
  convertible debentures (net of                       
  provision for income taxes of                        
  $244) (Note 5).......................           356          -        356          -
                                             --------   --------   --------   -------- 
                                                       
Net income (loss)......................      $  2,293   $(25,934)  $  3,785   $(23,545)
                                             ========   ========   ========   ========
                                                       
Income per share-basic (Note 5):                   
  Income (loss) before extraordinary                   
  item.................................      $    .11   $  (1.54)  $    .19   $  (1.40)
                                             ========   ========   ========   ========
  Net Income (loss) per share..........      $    .13   $  (1.54)  $    .21   $  (1.40)
                                             ========   ========   ========   ========
  Weighted average shares outstanding..        17,662     16,886     17,638     16,841
                                             ========   ========   ========   ========
                                                       
Income per share-diluted (Note 5):                 
  Income (loss) before extraordinary                   
    item...............................      $    .10   $  (1.54)  $    .18   $  (1.40)
                                             ========   ========   ========   ========
  Net Income (loss) per share..........      $    .12   $  (1.54)  $    .20   $  (1.40)
                                             ========   ========   ========   ========
  Weighted average shares outstanding..        19,337     16,886     19,391     16,841
                                             ========   ========   ========   ========
 
</TABLE>

The accompanying notes are an integral part of these consolidated statements.

                                      -5-
                                             
<PAGE>
 
                        SYNETIC, INC. AND SUBSIDIARIES
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                  Six Months Ended December 31, 1997 and 1996
                                 (in thousands)
                                  (unaudited)
<TABLE>
<CAPTION>
 
                                                      1997        1996
                                                    ---------  ----------
<S>                                                 <C>        <C>
 
Cash flows from operating activities:
 Net income (loss)................................  $  3,785   $ (23,545)
 Adjustments to reconcile net income to
   net cash provided by operating activities:
      Write-off of purchased research and
       development costs..........................         -      28,600
      Gain on repurchase of convertible 
       debentures.................................      (356)          -
      Depreciation and amortization...............     1,928       1,163
 
 Changes in operating assets and liabilities:
      Accounts receivable, net....................      (155)        410
      Inventories.................................      (401)       (618)
      Other assets................................    (2,078)      1,277
      Accounts payable............................      (799)        235
      Accrued liabilities.........................     3,160          96
      Income taxes payable........................     2,876       3,351
      Other liabilities...........................    (3,084)          -
                                                    --------   ---------
        Net cash provided by
         operating activities.....................     4,876      10,969
                                                    --------   ---------
 
Cash flows from investing activities:
 Sales of marketable securities...................    19,365     218,457
 Purchase of marketable securities................   (17,539)   (229,202)
 Capital expenditures.............................    (4,014)     (2,668)
 Acquisition of businesses, net of cash acquired..         -         596
                                                    --------   ---------
        Net cash (used for)
         investing activities.....................    (2,188)    (12,817)
                                                    --------   ---------
 
Cash flows from financing activities:
 Payments for treasury stock......................      (216)     (1,712)
 Payments for repurchase of convertible 
   debentures.....................................    (4,842)          -
 Proceeds from exercises of stock options and
   401(k) purchases...............................     1,708       1,888
                                                    --------   ---------
        Net cash provided by (used for)
         financing activities.....................    (3,350)        176
                                                    --------   ---------
 
Net (decrease) in cash and cash equivalents.......      (662)     (1,672)
Cash and cash equivalents, beginning of period....    77,303      22,210
                                                    --------   ---------
Cash and cash equivalents, end of period..........  $ 76,641   $  20,538
                                                    ========   =========
 
</TABLE>
The accompanying notes are an integral part of these consolidated statements.

                                      -6-

<PAGE>
 
                         SYNETIC, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1)  Financial statement presentation:

     In the opinion of management, the accompanying consolidated financial
statements contain all normal and recurring adjustments necessary to present
fairly the financial position of Synetic, Inc. and subsidiaries (the "Company")
as of December 31, 1997 (unaudited) and June 30, 1997 (audited), the results of
their operations for the six months ended December 31, 1997 and 1996 (unaudited)
and the results of their operations and their cash flows for the six months
ended December 31, 1997 and 1996 (unaudited).

     Principles of Consolidation--

     The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned operating subsidiaries, Porex Corporation and
subsidiaries ("Porex"), Avicenna Systems Corp. ("Avicenna") and CareAgents,
Inc.("CareAgents"), after elimination of all material intercompany accounts and
transactions.

     The accounting policies followed by the Company are set forth in the Notes
to Consolidated Financial Statements included in the Company's Annual Report on
Form 10-K for the fiscal year ended  June 30, 1997 (the "1997 10-K"), which
notes are incorporated herein by reference.

     The results of operations for the interim periods presented are not
necessarily indicative of the results to be expected for the full fiscal year.

     Certain reclassifications have been made to prior year amounts to conform
to the current year presentation.

(2)  Inventories:

     Inventories consisted of the following (in thousands):
<TABLE>
<CAPTION>
 
                                        December 31,        June 30,
                                            1997              1997
                                   -----------------------  --------
                                         (unaudited)
<S>                                <C>                      <C>
     Raw materials and supplies..          $3,154              $2,672
     Work-in-process.............             672                 347
     Finished goods..............           2,080               2,486
                                           ------              ------
                                           $5,906              $5,505
                                           ======              ======
</TABLE>
(3)  Marketable securities:

     At December 31, 1997 and June 30, 1997, marketable securities consisted
primarily of U.S. Treasury Notes and Federal Agency Notes.

(4)  Computation of net income (loss) per share:

     Effective with the quarter ended December 31, 1997, the Company adopted
Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS
No. 128").  The new standard simplifies the computation of net income per share
and increases comparability to international standards.  Under SFAS No. 128,
basic net income per share is computed by dividing net income by the

                                      -7-
<PAGE>
 
weighted average number of common shares outstanding for the period. Diluted net
income per share reflects the potential dilution that could occur if securities
or other contracts to issue common stock were exercised or converted into common
stock. Dilutive securities consist of common stock which may be issuable upon
exercise of outstanding stock options as calculated using the treasury stock
method. The Company's 5% Convertible Subordinated Debentures due 2007 (the
"Convertible Debentures"), were not included in the computation of diluted net
income per share because their conversion price was greater than the average
market price of the Company's common stock during the periods presented and, if
included, would have had an anti-dilutive effect on net income per share for the
periods presented. All prior periods have been restated in compliance with SFAS
128.

(5)  Extraordinary item - Gain from the repurchase of Convertible Debentures:

     During the quarter and six months ended December 31, 1997, the Company
repurchased $5,500,000 face amount of Convertible Debentures which resulted in
the Company recording a $356,000 gain (net of provision for income taxes of
$244,000), or $.02 per share (basic and diluted).

(6)  Supplemental cash flow information (in thousands):

     For the six months ended December 31, 1997 and 1996, the Company recognized
tax benefits related to the exercise of stock options as increases to additional
paid-in capital and decreases to income taxes payable of $1,364,000 and
$4,542,000, respectively.
<TABLE>
<CAPTION>
 
                                             December 31,
     Cash paid during the periods for:       1997    1996
                                            ------  ------
<S>                                         <C>     <C>
     Interest......................         $4,108  $   -
     Income taxes..................            516   1,239
 
</TABLE>
 

                                      -8-
<PAGE>
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF
         RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     The historical operations of the Company are primarily related to its
plastics technology business.  All revenues and a significant majority of
operating expenses were derived from these operations.  As discussed below, the
consolidated financial statements for the three and six month periods ended
December 31, 1997 include certain costs associated with the Company's activities
in developing its healthcare communications business.

Consolidated Results of Operations:
---------------------------------- 

     Net sales for the quarter and six months ended December 31, 1997 increased
29.8% and 31.1% to $15,440,000 and $30,273,000, respectively, from $11,899,000
and $23,084,000 in the comparable prior year periods.  The sales of Interflo
Technologies Inc. ("Interflo"), a company acquired in February 1997, accounted
for $1,330,000 and $2,941,000 of the increases in sales for the quarter and six
months ended December 31, 1997, respectively.  The balance of the increases in
sales for the periods was due principally to significant increased sales of
writing instrument components, increased sales to medical original equipment
manufacturers of porous components used in diagnostic products, and increased
sales of porous plastic components to the industrial market, including
components used in electronic devices.

     Cost of sales for the quarter and six months ended December 31, 1997
increased by $1,707,000, or 26.9%, and $3,897,000, or 31.2%, respectively, over
the comparable prior year periods due to the increased sales volume noted above
and, to a lesser extent, additional depreciation for equipment associated with
process improvements.  As a percent of net sales, cost of sales for the quarter
ended December 31, 1997 decreased to 52.2% from 53.3% in the comparable prior
year period principally due to increased leverage of certain fixed costs and
improvements in material usage.   As a percent of net sales, cost of sales for
the six months ended December 31, 1997 did not vary materially from the
comparable prior year period.

     Selling, general and administrative expenses for the quarter and six months
ended December 31, 1997 increased by $3,231,000 or 84.2% and $6,162,000 or
81.2%, respectively, over the comparable prior year periods due primarily to the
inclusion of $2,390,000 and $4,689,000, respectively, in expenses associated
with the Company's healthcare communications business which related primarily to
research and development activities for which there was no comparable amount in
the prior year periods.  Excluding these costs, as a percent of net sales,
selling, general and administrative expenses for the quarter and six months
ended December 31, 1997 decreased to 30.3% and 29.9%, respectively, from 32.3%
and 32.9% in the comparable prior year periods due principally to an increase in
sales which was not proportionately offset by expenses, since a portion of these
expenses is fixed and does not vary directly with sales.

     Interest and other income, net of interest expense for the quarter and six
months ended December 31, 1997 increased by $468,000 or 20% and $1,064,000, or
23.3% respectively, over the comparable prior year periods principally as a
result of an increase in funds available for investment generated by the
proceeds of the Company's Convertible Debentures issued in February 1997,
partially offset by the interest expense associated with the Convertible
Debentures.

                                      -9-
<PAGE>
 
     During the quarter ended December 31, 1996, the Company recorded a charge
to income of $28,600,000 for purchased research and development costs relating
to the acquisition of Avicenna.

     Excluding the purchased research and development charge in the prior year
periods for which no tax benefit was recognized, the effective tax rate for the
quarter and six months ended December 31, 1997 increased to 38.0% and 40.6%,
respectively, from 34.3% and 33.3% in the comparable prior year periods as the
Company currently records no state tax benefit for the expenses associated with
its healthcare communications business and, to a lesser extent, due to the
change in composition of the Company's marketable securities resulting in a
decrease in investment income subject to the dividend received deduction.

     During the quarter ended December 31, 1997, the Company recorded an
extraordinary item related to the repurchase of $5,500,000 face amount of 
Convertible Debentures. The repurchase resulted in a $356,000 gain (net of 
provision for income taxes of $244,000).

Capital Resources and Liquidity:
------------------------------- 

     Cash, cash equivalents and marketable securities decreased by $2,488,000 to
$313,340,000 during the six months ended December 31, 1997 principally due to
the Company's repurchase of $5,500,000 face amount of Convertible Debentures and
the interest payment related to the Convertible Debentures, partially offset by
cash provided by operations.

     As a result of the continuing efforts in developing its healthcare
communications business, the Company expects to incur significant research and
development expenditures in connection with this new area of business until the
products and services are successfully developed and marketed.  During the six
months ended December 31, 1997, the Company incurred expenditures of
approximately $5,318,000 related to the development of its healthcare
communications business.  The Company believes that its cash flow from
operations and the income earned on its investments are sufficient to meet the
anticipated working capital requirements of its business, including the research
and development expenditures noted above.

     The Company continues to pursue an acquisition program pursuant to which it
seeks to effect one or more acquisitions or other similar business combinations
with businesses it believes have significant growth potential. Financing for
such acquisitions may come from several sources, including, without limitation,
(a) the Company's cash, cash equivalents and marketable securities and (b)
proceeds from the incurrence of additional indebtedness or the issuance of
common stock, preferred stock, convertible debt or other securities. There can
be no assurance that the Company's acquisition program will be successful. See
"Item 1. Business--Acquisition Program" in the 1997 10-K.

                                      -10-
<PAGE>
 
                         SYNETIC INC. AND SUBSIDIARIES

PART II.  OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

     (a)  Exhibits

          Exhibit No.                  Description
          -----------                  -----------

             11                        Computation of Earnings Per Share

             27                        Financial Data Schedule


     (b)  On November 18, 1997, the Company filed a report on Form 8-K
          disclosing the filing of a registration statement with the Commission
          relating to the initial public offering by Porex Corporation, a
          wholly-owned subsidiary of the Company of 2,500,000 shares of common
          stock.


                                      -11-
<PAGE>
 
                                   SIGNATURE

          Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.

                                    SYNETIC, INC.

                                    /s/ Anthony Vuolo
                                    -----------------
                                    Vice President and
                                    Chief Financial Officer

Dated: July 7, 1998

                                      -12-
<PAGE>
 
                                 EXHIBIT INDEX

          Number                                 Description
          ------                                 -----------

            11                                   Computation of Earnings Per
                                                 Share

            27                                   Financial Data Schedule